Press Releases Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
1.61 ^USD	-3.59%		+7.33%	-40.37%

Apr. 22	Enlivex Therapeutics Says First Two Patients Dosed in Knee Osteoarthritis Trial	MT
Apr. 16	Enlivex Therapeutics Receives Approval to Expand Trial of Allocetra to Treat Knee Osteoarthritis Into Denmark	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Enlivex Therapeutics : Report of Periodic or Interim Report	Apr. 30	PU
Enlivex CEO Issues Letter to Shareholders – Perspectives on Recent Events	Apr. 29	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	Apr. 22	GL
Enlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee Osteoarthritis	Apr. 22	AQ
Enlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee Osteoarthritis	Apr. 16	GL
Enlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with Sepsis	Apr. 11	GL
Enlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With Sepsis	Apr. 11	GL
Enlivex Therapeutics : Notes to Consolidated Financial Statements - Form 6-K	Mar. 29	PU
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	Feb. 07	GL
Enlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing Method	Feb. 07	AQ
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	Jan. 17	GL
Enlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee Osteoarthritis	Jan. 17	AQ
Enlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With Sepsis	Dec. 20	GL
ENLIVEX THERAPEUTICS : CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 ENLIVEX THERAPEUTICS LTD. CONDENSED CONSOLIDATED FINANCIAL STATEMENTS AS OF SEPTEMBER 30, 2023 AND DECEMBER 31, 2022 AND FOR THE THREE AND NINE MONTH PERIODS ENDED SEPTEMBER 30, 2023 AND 2022 INDEX TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS - Form 6-K	Nov. 09	PU
Enlivex Therapeutics : Purchase Agreement - Form 6-K	Nov. 07	PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K	Nov. 02	PU
Enlivex Therapeutics : Annual General Meeting of Shareholders - Form 6-K	23-10-26	PU
Enlivex Therapeutics : Report Of Foreign Private Issuer - Form 6-K	23-09-18	PU
Enlivex Therapeutics : Immediate Report of Meeting	23-09-13	PU
ENLIVEX THERAPEUTICS : NOTICE OF ANNUAL GENERAL MEETING OF SHAREHOLDERS - Form 6-K	23-09-13	PU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Enlivex Therapeutics Ltd.

Equities

ENLV

IL0011319527

Press Releases

Filters